Trial Profile
A phase I safety and immunogenicity trial of an alphavirus replicon HIV subtype C gag vaccine (AVX101, Alphavax, Inc.) in healthy HIV-1 uninfected adult volunteers
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs AVX 101 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- 29 Jun 2012 Actual end date (1 Jul 2005) added as reported by ClinicalTrials.gov.
- 29 Jun 2012 Actual initiation date (1 Jul 2003), drug company (AlphaVax), additional lead trial centre and actual patient number 48 added as reported by ClinicalTrials.gov.
- 15 Oct 2005 New trial record.